Lannett Company ($LCI) announced receiving the FDA approval for its Abbreviated New Drug Application for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg. The drug is the therapeutic equivalent to, Nexium Delayed-Release Capsules, 20 mg and 40 mg.
Cellect Biotechnology Ltd. ($APOP) announced that its ApoGraft has been granted the Orphan Drug status by the FDA. The drug is designed for preventing acute and chronic graft versus host disease (GvHD) in transplant patients. The company is expected to announce top line data from a Phase 1/2 study in the first quarter of 2018.